ALB and neoplasm: Given that albumin-based carriers for anticancer therapeutics has shown promising results in both preclinical and clinical studies not only through half-life prolongation but also enhanced tumor localization [55], it is of great interest to investigate whether albumin associated hIL15-ABD will obtain a more favorable biodistribution profile, thereby increasing anticancer effects while reducing toxicity to normal organs.